Obesity is becoming more common in adults and adolescents, leading to a variety of gastroesophageal reflux disease-related disorders such as Barret's oesophagus (BE), esophageal erosions, and esophageal cancer. Furthermore, the rising frequency of gastrointestinal illnesses such as duodenal ulcers, Barrett's oesophagus, and non-erosive reflux disease (NERD) is likely to fuel the worldwide proton pump inhibitor market. The growing presence of local/generic medicine makers is also propelling the industry. Also, a robust product pipeline, as well as the approval of novel proton pump inhibitor medications for the treatments of gastroesophageal reflux disease (GERD) and ulcers is driving the market. The market's constraints and challenges are as follows: Proton pump inhibitors raise the risk of Clostridium difficile infection of the colon, and long-term use of PPI may increase the risk of osteoporosis-related hip, wrist, or spine fractures. COVID-19 can have an influence in three ways: directly impacting production and demand, disrupting distribution systems, and having a financial impact on enterprises and financial markets.
According to Coherent Market Insights, the global Proton Pump Inhibitors Market is estimated to be valued at US$ 2.9 billion in 2020 and is expected to exhibit a CAGR of 4.30% during the forecast period (2020-2027).
Key Companies in the Proton Pump Inhibitors Industry:
1. AstraZeneca PLC/AB
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc., Neurimmune AG, Ionis Pharmaceuticals, Inc., Proteros Biostructures GmbH, Sierra Oncology, Inc.
2. Bayer AG
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
3. Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc
4. Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan. On May 15, 2019 – Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners (“Frazier”) today announced a collaboration to launch Phathom Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders.
5. Sanofi S.A
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. Sanofi was founded in 1973 and is headquartered in Paris, France. It also has a collaboration and license option agreement with Prellis Biologics, Inc. in 2021 December, Sanofi to acquired Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics.
6. Aurobindo Pharma
Founded in 1986, the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and anti-biotics, among others. Headquartered in Hyderabad, India.
7. Perrigo Company plc
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
8. Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and others segments. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. On Feb 2021, Dr. Reddy’s Laboratories has introduced an orally disintegrating formulation of lansoprazole to the U.S. market. Lansoprazole is a proton pump inhibitor, a mechanism of action designed to reduce the amount of acid made in the stomach and thereby treat conditions including indigestion, heartburn, acid reflux and gastroesophageal reflux disease.
9. RedHill Biopharma Ltd (ADR)
RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel. RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. On January 2022, RedHill Biopharma and Gaelan Medical Enter into License Agreement for Talicia® for the United Arab Emirates. Talicia is a U.S. FDA-approved treatment for H. pylori, a bacterial infection that affects more than 50% of the world's adult population representing significant unmet need.
10. Cipla Limited
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company was incorporated in 1935 and is headquartered in Mumbai, India. Cipla Limited has a licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; a license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir.
*Definition-Proton pump inhibitors are medications that are primarily used to reduce stomach acid levels in people who have gastroesophageal reflux disease, hyperacidity, or ulcers.
